Welcome to our dedicated page for Baxter Intl news (Ticker: BAX), a resource for investors and traders seeking the latest updates and insights on Baxter Intl stock.
Baxter International Inc (NYSE: BAX) is a global healthcare leader specializing in life-saving renal care, advanced medical devices, and hospital solutions. This page provides investors and healthcare professionals with timely updates on the company’s operational developments, regulatory milestones, and strategic initiatives.
Access authoritative information about Baxter’s latest financial results, product innovations, and partnerships. Our curated news collection simplifies tracking of critical updates across key areas including dialysis technologies, infusion systems, and biosurgery products.
Discover official announcements regarding:
• Quarterly earnings and financial guidance
• New product approvals and clinical trials
• Strategic acquisitions in medical technology
• Regulatory compliance updates
• Leadership changes and corporate governance
Bookmark this page for streamlined access to Baxter’s verified news developments. Check regularly for updates that may impact market positioning and healthcare sector trends.
Baxter International (NYSE:BAX) announced the immediate retirement of José (Joe) E. Almeida from his positions as Chair, President, and CEO. Lead Independent Director Brent Shafer has been appointed as Chair and Interim CEO, with the board initiating a comprehensive search for a permanent CEO.
The company also appointed Heather Knight as Executive Vice President and Chief Operating Officer, responsible for global operations including sales, marketing, R&D, supply chain, and medical affairs. Nancy Schlichting will assume the role of lead independent director.
Baxter recently completed the sale of its Kidney Care business to Carlyle on January 31, 2025. The company expects Q4 and full-year 2024 results to align with previous guidance, maintaining its 2025 objectives of 4-5% operational sales growth and approximately 16.5% adjusted operating margin. However, these projections don't include potential impacts from recently announced U.S. tariffs on imports from Mexico, Canada, and China.
Baxter International (NYSE:BAX), a global medtech leader, has announced it will host a conference call to discuss its fourth-quarter 2024 financial results on Thursday, February 13, 2025 at 7:30 a.m. Central Time. Investors can pre-register for the call through a provided registration link. The conference call will also be accessible via webcast through Baxter's website. The company notes that the call will be recorded and is copyrighted material, requiring Baxter's permission for any recording or rebroadcasting.
Baxter International (NYSE:BAX), a global medtech leader, has announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference. The company's chair, president and chief executive officer, José (Joe) E. Almeida, will deliver a presentation on Monday, January 13, 2025, at 10:30 a.m. Pacific Time. Interested parties can access the live webcast through www.baxter.com, with replay availability extending until July 12, 2025.
Baxter International (NYSE:BAX) announced five new injectable pharmaceutical product launches in the U.S., bringing their total launches to 10 in 2024. The new products include: Micafungin for Candida infections, Cyclophosphamide Injection for malignant diseases, Pantoprazole Sodium for GERD treatment, Cefazolin in a new 3g/150mL strength for various infections, and Levetiracetam for seizure treatment.
These ready-to-use formats utilize Baxter's proprietary container technology and are designed to improve operational efficiencies, simplify medication preparation, and enhance patient safety by reducing contamination risks and potential compounding errors.
Baxter International (NYSE:BAX) has announced its participation in the 7th Annual Evercore HealthCONx Conference. Joel Grade, the company's chief financial officer, will deliver a presentation on Thursday, December 5, 2024, at 9:10 a.m. Eastern Time. The presentation will be accessible via live webcast on www.baxter.com and will remain available for replay until Tuesday, June 3, 2025.
Baxter International (NYSE:BAX) has announced its participation in the upcoming Jefferies London Healthcare Conference. The company's Chief Financial Officer, Joel Grade, will deliver a presentation on Wednesday, November 20, 2024, at 11:00 a.m. GMT. The presentation will be accessible through a live webcast on www.baxter.com, with replay availability extending through Monday, May 19, 2025.
Baxter International (NYSE:BAX) has announced its participation in the Stifel 2024 Healthcare Conference. Joel Grade, the company's chief financial officer, will deliver a presentation on Monday, November 18, 2024, at 8:35 a.m. Eastern Time. The presentation will be available via live webcast on www.baxter.com and can be accessed for replay through May 17, 2025.
Baxter International (NYSE:BAX) has declared a quarterly cash dividend of $0.17 per share of common stock, payable on Jan. 2, 2025, to stockholders of record as of Nov. 29, 2024. The indicated annual dividend rate is $0.68 per share. This new quarterly dividend rate is set in anticipation of the Kidney Care business segment divestiture to Carlyle, expected to close in late 2024 or early 2025. The dividend targets a payout ratio of approximately 25% of adjusted net income, aligning with peer companies. Baxter maintains its 93-year history of consistent dividend payments while balancing business reinvestment with shareholder returns.
Baxter (BAX) reported Q3 2024 total sales of $3.85 billion, with continuing operations sales of $2.70 billion increasing 4% on both reported and constant currency basis. The company achieved total U.S. GAAP diluted EPS of $0.27 and adjusted EPS of $0.80, exceeding previous guidance. Hurricane Helene significantly impacted the North Cove facility, though production has restarted on the highest-throughput IV solutions line. The company announced the pending sale of its Kidney Care business to Carlyle for $3.80 billion, expected to close in late 2024 or early 2025. Due to hurricane impact, Baxter adjusted its full-year 2024 outlook, expecting total company sales growth of 1-2% and adjusted EPS of $2.90-$2.94.
Baxter International (NYSE:BAX) announced its participation in the upcoming UBS Global Healthcare Conference. Chief Financial Officer Joel Grade will deliver a presentation on Wednesday, November 13, 2024, at 1:15 p.m. Pacific Time. The presentation will be accessible through a live webcast on www.baxter.com, with replay availability extending through Monday, May 12, 2025.
